<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39576781</PMID><DateCompleted><Year>2024</Year><Month>11</Month><Day>22</Day></DateCompleted><DateRevised><Year>2024</Year><Month>11</Month><Day>24</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1932-6203</ISSN><JournalIssue CitedMedium="Internet"><Volume>19</Volume><Issue>11</Issue><PubDate><Year>2024</Year></PubDate></JournalIssue><Title>PloS one</Title><ISOAbbreviation>PLoS One</ISOAbbreviation></Journal><ArticleTitle>Association between long COVID and nonsteroidal anti-inflammatory drug use by patients with acute-phase COVID-19: A nationwide Korea National Health Insurance Service cohort study.</ArticleTitle><Pagination><StartPage>e0312530</StartPage><MedlinePgn>e0312530</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e0312530</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1371/journal.pone.0312530</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">Long coronavirus disease (COVID) poses a significant burden following the coronavirus disease 2019 (COVID-19) pandemic. Debate persists regarding the impact of nonsteroidal anti-inflammatory drug (NSAID) administration during acute-phase COVID-19 on the development of long COVID. Hence, this study aimed to assess the potential association between NSAID use and long COVID using data from patients with COVID-19 in Korea's National Health Insurance Service.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">This nested case-control study defined the study cohort as patients diagnosed with COVID-19 for the first time between 2020 and 2021. The primary exposure investigated was NSAID prescriptions within 14 days of the initial COVID-19 diagnosis. We used propensity score matching to create three control patients matched to each patient in the NSAID exposure group. Odds ratios (ORs) and 95% confidence intervals (CIs) were calculated after the adjustment for demographics, Charlson Comorbidity Index, and existing comorbidities.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Among the 225,458 patients diagnosed with COVID-19, we analyzed data from 254 with long COVID. The adjusted OR (aOR) for NSAID exposure during acute-phase COVID-19 was higher in long COVID cases versus controls (aOR, 1.79; 95% CI, 1.00-3.19), suggesting a potential relationship. However, a sensitivity analysis revealed that the increased odds of NSAID exposure in the acute phase became statistically non-significant (aOR, 1.64; 95% CI, 0.90-2.99) when COVID-19 self-quarantine duration was included as a covariate. Additionally, acetaminophen exposure was not significantly associated (aOR, 1.12; 95% CI, 0.75-1.68), while antiviral drugs demonstrated a stronger association (aOR, 3.75; 95% CI, 1.66-8.48).</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Although this study suggests a possible link between NSAID use in the acute COVID-19 infection stage and a higher risk of long COVID as well as both NSAID and acetaminophen use during the chronic COVID-19 period and a lower risk of long COVID, the association was not statistically significant. Further research is needed to determine the causal relationship between the various treatment options for acute COVID-19 and the development of long COVID.</AbstractText><CopyrightInformation>Copyright: &#xa9; 2024 Lee et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Ye-Seul</ForeName><Initials>YS</Initials><Identifier Source="ORCID">0000-0001-6127-5401</Identifier><AffiliationInfo><Affiliation>Jaseng Spine and Joint Research Institute, Jaseng Medical Foundation, Seoul, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Heejun</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0001-5907-6059</Identifier><AffiliationInfo><Affiliation>Jaseng Spine and Joint Research Institute, Jaseng Medical Foundation, Seoul, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kwon</LastName><ForeName>Sunoh</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-0942-8164</Identifier><AffiliationInfo><Affiliation>Korean Medicine Convergence Research Division, Korea Institute of Oriental Medicine, Daejeon, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Tae-Hun</ForeName><Initials>TH</Initials><Identifier Source="ORCID">0000-0002-8448-3219</Identifier><AffiliationInfo><Affiliation>Korean Medicine Clinical Trial Center, Korean Medicine Hospital, Kyung Hee University, Seoul, Republic of Korea.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>11</Month><Day>22</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>PLoS One</MedlineTA><NlmUniqueID>101285081</NlmUniqueID><ISSNLinking>1932-6203</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000894">Anti-Inflammatory Agents, Non-Steroidal</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000894" MajorTopicYN="Y">Anti-Inflammatory Agents, Non-Steroidal</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D056910" MajorTopicYN="N" Type="Geographic">Republic of Korea</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009313" MajorTopicYN="N">National Health Programs</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>The authors have declared that no competing interests exist.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>8</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>10</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>11</Month><Day>22</Day><Hour>18</Hour><Minute>17</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>11</Month><Day>22</Day><Hour>18</Hour><Minute>16</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>11</Month><Day>22</Day><Hour>13</Hour><Minute>33</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>11</Month><Day>22</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39576781</ArticleId><ArticleId IdType="pmc">PMC11584118</ArticleId><ArticleId IdType="doi">10.1371/journal.pone.0312530</ArticleId><ArticleId IdType="pii">PONE-D-24-33236</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Yelin D, Moschopoulos CD, Margalit I, Gkrania-Klotsas E, Landi F, Stahl J-P, et al.. ESCMID rapid guidelines for assessment and management of long COVID. Clinical Microbiology and Infection. 2022;28(7):955&#x2013;72. doi: 10.1016/j.cmi.2022.02.018</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmi.2022.02.018</ArticleId><ArticleId IdType="pmc">PMC8849856</ArticleId><ArticleId IdType="pubmed">35182760</ArticleId></ArticleIdList></Reference><Reference><Citation>Crook H, Raza S, Nowell J, Young M, Edison P. Long covid&#x2014;mechanisms, risk factors, and management. bmj. 2021;374.</Citation><ArticleIdList><ArticleId IdType="pubmed">34312178</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim Y, Kim S-W, Chang H-H, Kwon KT, Bae S, Hwang S. Post-acute COVID-19 syndrome in patients after 12 months from COVID-19 infection in Korea. BMC infectious diseases. 2022;22(1):93. doi: 10.1186/s12879-022-07062-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12879-022-07062-6</ArticleId><ArticleId IdType="pmc">PMC8793328</ArticleId><ArticleId IdType="pubmed">35086489</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoffmann M, Kleine-Weber H, Schroeder S, Kr&#xfc;ger N, Herrler T, Erichsen S, et al.. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. cell. 2020;181(2):271&#x2013;80. e8. doi: 10.1016/j.cell.2020.02.052</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2020.02.052</ArticleId><ArticleId IdType="pmc">PMC7102627</ArticleId><ArticleId IdType="pubmed">32142651</ArticleId></ArticleIdList></Reference><Reference><Citation>Jeong HE, Lee H, Shin HJ, Choe YJ, Filion KB, Shin J-Y. Association between nonsteroidal antiinflammatory drug use and adverse clinical outcomes among adults hospitalized with coronavirus 2019 in South Korea: a nationwide study. Clinical Infectious Diseases. 2021;73(11):e4179&#x2013;e88. doi: 10.1093/cid/ciaa1056</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciaa1056</ArticleId><ArticleId IdType="pmc">PMC7454423</ArticleId><ArticleId IdType="pubmed">32717066</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun-Min Kim Y-IK. National Health Insurance Statistical Yearbook. Health Insurance Review &amp; Assessment, National Health Insurance Service Korea. 2020.</Citation></Reference><Reference><Citation>Kim S, Kim MS, You SH, Jung SY. Conducting and Reporting a Clinical Research Using Korean Healthcare Claims Database. Korean J Fam Med. 2020;41(3):146&#x2013;52. Epub 20200520. doi: 10.4082/kjfm.20.0062 ; PubMed Central PMCID: PMC7272364.</Citation><ArticleIdList><ArticleId IdType="doi">10.4082/kjfm.20.0062</ArticleId><ArticleId IdType="pmc">PMC7272364</ArticleId><ArticleId IdType="pubmed">32456382</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim Y, Kim SE, Kim T, Yun KW, Lee SH, Lee E, et al.. Preliminary guidelines for the clinical evaluation and management of long COVID. Infection &amp; chemotherapy. 2022;54(3):566. doi: 10.3947/ic.2022.0141</Citation><ArticleIdList><ArticleId IdType="doi">10.3947/ic.2022.0141</ArticleId><ArticleId IdType="pmc">PMC9533168</ArticleId><ArticleId IdType="pubmed">36196612</ArticleId></ArticleIdList></Reference><Reference><Citation>McCaffrey DF, Griffin BA, Almirall D, Slaughter ME, Ramchand R, Burgette LF. A tutorial on propensity score estimation for multiple treatments using generalized boosted models. Stat Med. 2013;32(19):3388&#x2013;414. Epub 20130318. doi: 10.1002/sim.5753 ; PubMed Central PMCID: PMC3710547.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/sim.5753</ArticleId><ArticleId IdType="pmc">PMC3710547</ArticleId><ArticleId IdType="pubmed">23508673</ArticleId></ArticleIdList></Reference><Reference><Citation>Parisien M, Lima LV, Dagostino C, El-Hachem N, Drury GL, Grant AV, et al.. Acute inflammatory response via neutrophil activation protects against the development of chronic pain. Sci Transl Med. 2022;14(644):eabj9954. Epub 20220511. doi: 10.1126/scitranslmed.abj9954 ; PubMed Central PMCID: PMC10317000.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.abj9954</ArticleId><ArticleId IdType="pmc">PMC10317000</ArticleId><ArticleId IdType="pubmed">35544595</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen JS, Alfajaro MM, Chow RD, Wei J, Filler RB, Eisenbarth SC, et al.. Nonsteroidal anti-inflammatory drugs dampen the cytokine and antibody response to SARS-CoV-2 infection. Journal of virology. 2021;95(7): doi: 10.1128/JVI.00014-21</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.00014-21</ArticleId><ArticleId IdType="pmc">PMC8092681</ArticleId><ArticleId IdType="pubmed">33441348</ArticleId></ArticleIdList></Reference><Reference><Citation>Peluso MJ, Ryder D, Flavell RR, Wang Y, Levi J, LaFranchi BH, et al.. Tissue-based T cell activation and viral RNA persist for up to 2 years after SARS-CoV-2 infection. Sci Transl Med. 2024;16(754):eadk3295. Epub 20240703. doi: 10.1126/scitranslmed.adk3295 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.adk3295</ArticleId><ArticleId IdType="pmc">PMC11337933</ArticleId><ArticleId IdType="pubmed">38959327</ArticleId></ArticleIdList></Reference><Reference><Citation>Saito S, Shahbaz S, Osman M, Redmond D, Bozorgmehr N, Rosychuk RJ, et al.. Diverse immunological dysregulation, chronic inflammation, and impaired erythropoiesis in long COVID patients with chronic fatigue syndrome. J Autoimmun. 2024;147:103267. Epub 20240525. doi: 10.1016/j.jaut.2024.103267 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaut.2024.103267</ArticleId><ArticleId IdType="pubmed">38797051</ArticleId></ArticleIdList></Reference><Reference><Citation>Cogliandro V, Bonfanti P. Long COVID: lights and shadows on the clinical characterization of this emerging pathology. The new microbiologica. 2024;47(1):15&#x2013;27.</Citation><ArticleIdList><ArticleId IdType="pubmed">38700879</ArticleId></ArticleIdList></Reference><Reference><Citation>Day M. Covid-19: ibuprofen should not be used for managing symptoms, say doctors and scientists. British Medical Journal Publishing Group. 2020.</Citation><ArticleIdList><ArticleId IdType="pubmed">32184201</ArticleId></ArticleIdList></Reference><Reference><Citation>Voiriot G, Dury S, Parrot A, Mayaud C, Fartoukh M. Nonsteroidal antiinflammatory drugs may affect the presentation and course of community-acquired pneumonia. Chest. 2011;139(2):387&#x2013;94. doi: 10.1378/chest.09-3102</Citation><ArticleIdList><ArticleId IdType="doi">10.1378/chest.09-3102</ArticleId><ArticleId IdType="pubmed">20724739</ArticleId></ArticleIdList></Reference><Reference><Citation>Kushner P, McCarberg BH, Grange L, Kolosov A, Haveric AL, Zucal V, et al.. The use of non-steroidal anti-inflammatory drugs (NSAIDs) in COVID-19. NPJ Primary Care Respiratory Medicine. 2022;32(1):35. doi: 10.1038/s41533-022-00300-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41533-022-00300-z</ArticleId><ArticleId IdType="pmc">PMC9489480</ArticleId><ArticleId IdType="pubmed">36127354</ArticleId></ArticleIdList></Reference><Reference><Citation>Reese JT, Coleman B, Chan L, Blau H, Callahan TJ, Cappelletti L, et al.. NSAID use and clinical outcomes in COVID-19 patients: a 38-center retrospective cohort study. Virology journal. 2022;19(1):84. doi: 10.1186/s12985-022-01813-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12985-022-01813-2</ArticleId><ArticleId IdType="pmc">PMC9107579</ArticleId><ArticleId IdType="pubmed">35570298</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>